SAN DIEGO, June 12, 2017 /PRNewswire/ -- Trovagene, Inc.
(NASDAQ: TROV), a precision medicine biotechnology company
today announced it has entered into an agreement with AstraZeneca
to provide Trovera® urine ctDNA biomarker test and
services.
The Trovera® EGFR urine liquid biopsy test will initially
be used in an open label prospective biomarker study evaluating
whether the combined use of noninvasive testing (urine and blood
testing) is as effective as tissue testing in identifying epidermal
growth factor receptor (EGFR) T790M mutation status.
"We're pleased to partner with AstraZeneca and to have our urine
liquid biopsy test included in a trial designed to explore new and
non-invasive ways to detect if patients have this EGFR
mutation and may be appropriate for specific treatment options,"
said Bill Welch, Chief Executive
Officer of Trovagene. "This agreement marks a major milestone
for Trovagene."
Trovagene performs CLIA laboratory testing services for other
biopharmaceutical companies and clinical research third
parties. This expertise is supportive of the development of
biomarkers for Trovagene's internal drug development program for
PCM-075, a polo-like kinase 1 (PLK1) inhibitor. Trovagene plans to
use an acute myeloid leukemia (AML) genetic panel to assess patient
response to PCM-075 in its phase 1/2 trial.
About Trovagene, Inc.
Trovagene is a precision medicine biotechnology company
developing oncology therapeutics for improved cancer care by
leveraging its proprietary Precision Cancer Monitoring® (PCM)
technology in tumor genomics. Trovagene has broad
intellectual property and proprietary technology to measure
circulating tumor DNA (ctDNA) in urine and blood to identify and
quantify clinically actionable markers for predicting response to
cancer therapies. Trovagene offers its PCM technology at its
CLIA/CAP – accredited laboratory and plans to continue to
vertically integrate its PCM technology with precision cancer
therapeutics. For more information, please
visit www.trovagene.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of words
such as "anticipate," "believe," "forecast," "estimated" and
"intend" or other similar terms or expressions that concern
Trovagene's expectations, strategy, plans or intentions. These
forward-looking statements are based on Trovagene's current
expectations and actual results could differ materially.
There are a number of factors that could cause actual events
to differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
our need for additional financing; our ability to continue as a
going concern; clinical trials involve a lengthy and expensive
process with an uncertain outcome, and results of earlier studies
and trials may not be predictive of future trial results; our
clinical trials may be suspended or discontinued due to unexpected
side effects or other safety risks that could preclude approval of
our product candidates; uncertainties of government or third party
payer reimbursement; dependence on key personnel; limited
experience in marketing and sales; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; our ability to develop tests, kits and systems and
the success of those products; regulatory, financial and business
risks related to our international expansion and risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations. There are no guarantees that any of our
technology or products will be utilized or prove to be commercially
successful, or that Trovagene's strategy to design its liquid
biopsy tests to report on clinically actionable cancer genes will
ultimately be successful or result in better reimbursement
outcomes. Additionally, there are no guarantees that future
clinical trials will be completed or successful or that any
precision medicine therapeutics will receive regulatory approval
for any indication or prove to be commercially successful.
Investors should read the risk factors set forth in Trovagene's
Form 10-K for the year ended December 31, 2016, and other
periodic reports filed with the Securities and Exchange
Commission. While the list of factors presented here is
considered representative, no such list should be considered to be
a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles
to the realization of forward-looking statements.
Forward-looking statements included herein are made as of the
date hereof, and Trovagene does not undertake any obligation to
update publicly such statements to reflect subsequent events or
circumstances.
Trovagene Contact:
Vicki Kelemen
VP, Corporate Communications
858-952-7652
vkelemen@trovagene.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/trovagene-enters-into-agreement-with-astrazeneca-to-utilize-trovera-ctdna-test-and-services-in-prospective-biomarker-study-300472057.html
SOURCE Trovagene, Inc.